Envestnet Asset Management Inc. Raises Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Envestnet Asset Management Inc. lifted its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 34.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 926,699 shares of the medical instruments supplier's stock after purchasing an additional 235,058 shares during the quarter. Envestnet Asset Management Inc. owned 0.32% of Becton, Dickinson and Company worth $210,240,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Bank of Jackson Hole Trust bought a new position in Becton, Dickinson and Company during the 4th quarter valued at about $25,000. Sierra Ocean LLC purchased a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at approximately $29,000. Picton Mahoney Asset Management lifted its position in Becton, Dickinson and Company by 61.4% during the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock valued at $32,000 after purchasing an additional 54 shares during the period. Hopwood Financial Services Inc. purchased a new stake in Becton, Dickinson and Company in the fourth quarter worth approximately $39,000. Finally, Versant Capital Management Inc grew its position in Becton, Dickinson and Company by 54.1% in the 4th quarter. Versant Capital Management Inc now owns 208 shares of the medical instruments supplier's stock worth $47,000 after purchasing an additional 73 shares during the period. 86.97% of the stock is owned by institutional investors.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Richard Byrd sold 1,940 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $224.91, for a total transaction of $436,325.40. Following the completion of the sale, the executive vice president now directly owns 7,411 shares of the company's stock, valued at $1,666,808.01. This trade represents a 20.75 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP David Shan sold 500 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the sale, the executive vice president now owns 5,741 shares in the company, valued at approximately $1,377,840. The trade was a 8.01 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 4,675 shares of company stock valued at $1,057,182 over the last ninety days. 0.36% of the stock is currently owned by company insiders.

Remove Ads

Becton, Dickinson and Company Stock Performance

Shares of BDX stock traded up $2.42 during trading hours on Friday, reaching $201.54. 1,850,652 shares of the company traded hands, compared to its average volume of 1,685,646. The firm has a 50-day moving average price of $223.97 and a 200 day moving average price of $229.86. The company has a market cap of $57.87 billion, a P/E ratio of 33.48, a P/E/G ratio of 1.63 and a beta of 0.35. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63. Becton, Dickinson and Company has a 12-month low of $193.03 and a 12-month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company announced that its Board of Directors has initiated a stock buyback program on Tuesday, January 28th that permits the company to repurchase 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares repurchase programs are typically a sign that the company's management believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, March 31st. Shareholders of record on Monday, March 10th were paid a $1.04 dividend. The ex-dividend date of this dividend was Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 2.06%. Becton, Dickinson and Company's payout ratio is presently 69.10%.

Analysts Set New Price Targets

Several research firms have recently weighed in on BDX. Barclays lowered their price target on Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating on the stock in a report on Monday, April 7th. StockNews.com raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Wednesday, April 2nd. Finally, Piper Sandler upped their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an "overweight" rating in a research report on Tuesday, January 28th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of "Buy" and an average target price of $275.71.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.